The objectives of this study were to describe the pharmacokinetics of firocoxib following oral (PO) dosing and intravenous (IV) injection in sows. Seven healthy sows were administered 0.5 mg firocoxib/kg IV. Following a 23‐d washout period, sows were administered firocoxib at 4.0 mg firocoxib/kg PO. Blood samples were collected at predetermined times for 72 hr after IV and 120 hr after PO administration. Plasma firocoxib concentration was measured using UPLC‐MS/MS, and pharmacokinetic analysis was performed using noncompartmental procedures. Tissue firocoxib concentrations were determined at 5, 10 (n = 2/time point), and 21 d (n = 3) after PO administration. The geometric mean half‐life following IV and PO administration was 16.6 and 22.5 hr, respectively. A mean peak plasma concentration (Cmax) of 0.06 µg/ml was recorded at 7.41 hr (T_max) after oral administration. Mean oral bioavailability was determined to be 70.3%. No signs of NSAID toxicity were observed on macroscopic and microscopic investigation. Firocoxib was detected in the skin with subcutaneous fat (0.02 µg/g) of one of three sows at 21 days postadministration. Additional work to establish appropriate meat withhold intervals in sows is required. Firocoxib was readily absorbed following PO administration. Further work is needed to better understand the analgesic effects for sows and piglets nursing sows administered firocoxib.

中文翻译：

---

口服后母猪中非洛昔布的药代动力学和组织浓度。

这项研究的目的是描述母猪口服（PO）剂量和静脉（IV）注射后非洛昔布的药代动力学。七只健康的母猪静脉注射0.5 mg fireocoxib / kg。经过23天的冲洗期后，母猪以4.0 mg / ml / kg / kg POOC的剂量给予foxocibib。在静脉注射后72小时和PO给药后120小时的预定时间收集血样。使用UPLC-MS / MS测量血浆非洛昔布浓度，并使用非房室程序进行药代动力学分析。在5、10（n  = 2 /时间点）和21 d（n = 3）给药后。IV和PO给药后的几何平均半衰期分别为16.6和22.5小时。口服后7.41小时（T _max）记录的平均血浆峰值浓度（Cmax）为0.06 µg / ml 。口服平均生物利用度确定为70.3％。在宏观和微观研究中未观察到NSAID毒性的迹象。给药后21天，皮下脂肪（0.02 µg / g）的三只母猪之一在皮肤中检出了Firocoxib。需要进行额外的工作以在母猪中建立适当的肉类保留时间。口服PO后，Firocoxib很容易被吸收。需要做进一步的工作以更好地了解母猪和哺乳母猪使用氟罗昔布的镇痛效果。